MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

August 12, 2026

Study Completion Date

February 12, 2027

Conditions

Locally Advanced Rectal Cancer

Interventions

DRUG

PD-1 antibody

PD-1 antibody (Toripalimab): 240mg d1 q3w

DRUG

Oxaliplatin

Oxaliplatin: 130mg/m2 d1 q3w

DRUG

Capecitabine

Capecitabine: 1000mg/m2 bid d1-14 q3w

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER